Peripubertal cannabidiol treatment rescues behavioral and
neurochemical abnormalities in the MAM model of schizophrenia

J 2019

Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia

ŠTARK, Tibor; Jana RUDÁ; Fabio IANNOTI; Claudio D'ADDARIO; Roberta DI MARCO et. al.

Základní údaje

Originální název

Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia

Autoři

Vydání

Neuropharmacology, Oxford, Pergamon-Elsevier Science LTD, 2019, 0028-3908

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.431

Kód RIV

RIV/00216224:14110/19:00109798

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1016/j.neuropharm.2018.11.035

UT WoS

000457663900021

EID Scopus

2-s2.0-85058120018

Klíčová slova anglicky

Cannabidiol; Cannabinoid CB1 receptor; MAM model; Schizophrenia

Štítky

14110515, 14110516, CF CELLIM, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 10. 2024 12:49, Ing. Martina Blahová

Anotace

V originále

In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the anti mitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively. At the molecular level, an increased cannabinoid receptor type-1 (CB1) mRNA and protein expression, which might be due to reduction in DNA methylation at the gene promoter in the prefrontal cortex (PFC), coincided with deficits in the social interaction test and in the novel object recognition test in MAM rats. Both the schizophrenia-like phenotype and altered transcriptional regulation of CB1 receptors were reversed by peripubertal treatment (from PND 19 to PND 39) with the non-psychotropic phytocannabinoid cannabidiol (30 mg/kg/day), or, in part, by treatment with the cannabinoid CB1 receptor antagonist/inverse agonist AM251 (0.5 mg/kg/day), but not with haloperidol (0.6 mg/kg/day). These results suggest that early treatment with cannabidiol may prevent both the appearance of schizophrenia-like deficits as well as CB1 alterations in the PFC at adulthood, supporting that peripubertal cannabidiol treatment might be protective against MAM insult.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

MUNI/A/1132/2017, interní kód MU

Název: Behaviorální psychofarmakologie a farmakokinetika v preklinickém výzkumu léčiv

Investor: Masarykova univerzita, Behaviorální psychofarmakologie a farmakokinetika v preklinickém výzkumu léčiv, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

3SGA5789, interní kód MU

Název: PRECIPITATION OF SCHIZOPHRENIA-LIKE PHENOTYPE BY PRENATAL INFLUENCES: ASSESSING THE ROLE OF THE ENDOCANNABINOID SYSTEM (Akronym: ncRNAPain)

Investor: Jihomoravský kraj, PRECIPITATION OF SCHIZOPHRENIA-LIKE PHENOTYPE BY PRENATAL INFLUENCES: ASSESSING THE ROLE OF THE ENDOCANNABINOID SYSTEM, Granty pro zahraniční vědce

90062, velká výzkumná infrastruktura

Název: Czech-BioImaging

Citovat

ŠTARK, Tibor; Jana RUDÁ; Fabio IANNOTI; Claudio D'ADDARIO; Roberta DI MARCO; Vladimír PEKAŘÍK; Eva DRAŽANOVÁ; Fabiana PISCITELLI; Monica BARI; Zuzana BABINSKÁ; Giovanni GIURDANELLA; Martina DI BARTOLOMEO; Salvatore SALOMONE; Alexandra ŠULCOVÁ; Mauro MACCARRONE; Carsten WOTJAK; Zenon STARČUK; Filippo DRAGO; Raphael MECHOULAM; Vincenzo DI MARZO a Vincenzo MICALE. Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology. Oxford: Pergamon-Elsevier Science LTD, 2019, roč. 146, č. 1, s. 212-221. ISSN 0028-3908. Dostupné z: https://doi.org/10.1016/j.neuropharm.2018.11.035.

@article{1535717,
   author = {Štark, Tibor and Rudá, Jana and Iannoti, Fabio and D'Addario, Claudio and Di Marco, Roberta and Pekařík, Vladimír and Dražanová, Eva and Piscitelli, Fabiana and Bari, Monica and Babinská, Zuzana and Giurdanella, Giovanni and Di Bartolomeo, Martina and Salomone, Salvatore and Šulcová, Alexandra and Maccarrone, Mauro and Wotjak, Carsten and Starčuk, Zenon and Drago, Filippo and Mechoulam, Raphael and Di Marzo, Vincenzo and Micale, Vincenzo},
   article_location = {Oxford},
   article_number = {1},
   doi = {https://doi.org/10.1016/j.neuropharm.2018.11.035},
   keywords = {Cannabidiol; Cannabinoid CB1 receptor; MAM model; Schizophrenia},
   language = {eng},
   issn = {0028-3908},
   journal = {Neuropharmacology},
   title = {Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia},
   url = {https://www.sciencedirect.com/science/article/pii/S0028390818308761},
   volume = {146},
   year = {2019}
}

TY  - JOUR
ID  - 1535717
AU  - Štark, Tibor - Rudá, Jana - Iannoti, Fabio - D'Addario, Claudio - Di Marco, Roberta - Pekařík, Vladimír - Dražanová, Eva - Piscitelli, Fabiana - Bari, Monica - Babinská, Zuzana - Giurdanella, Giovanni - Di Bartolomeo, Martina - Salomone, Salvatore - Šulcová, Alexandra - Maccarrone, Mauro - Wotjak, Carsten - Starčuk, Zenon - Drago, Filippo - Mechoulam, Raphael - Di Marzo, Vincenzo - Micale, Vincenzo
PY  - 2019
TI  - Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia
JF  - Neuropharmacology
VL  - 146
IS  - 1
SP  - 212-221
EP  - 212-221
PB  - Pergamon-Elsevier Science LTD
SN  - 00283908
KW  - Cannabidiol
KW  - Cannabinoid CB1 receptor
KW  - MAM model
KW  - Schizophrenia
UR  - https://www.sciencedirect.com/science/article/pii/S0028390818308761
L2  - https://www.sciencedirect.com/science/article/pii/S0028390818308761
N2  - In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the anti mitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively. At the molecular level, an increased cannabinoid receptor type-1 (CB1) mRNA and protein expression, which might be due to reduction in DNA methylation at the gene promoter in the prefrontal cortex (PFC), coincided with deficits in the social interaction test and in the novel object recognition test in MAM rats. Both the schizophrenia-like phenotype and altered transcriptional regulation of CB1 receptors were reversed by peripubertal treatment (from PND 19 to PND 39) with the non-psychotropic phytocannabinoid cannabidiol (30 mg/kg/day), or, in part, by treatment with the cannabinoid CB1 receptor antagonist/inverse agonist AM251 (0.5 mg/kg/day), but not with haloperidol (0.6 mg/kg/day). These results suggest that early treatment with cannabidiol may prevent both the appearance of schizophrenia-like deficits as well as CB1 alterations in the PFC at adulthood, supporting that peripubertal cannabidiol treatment might be protective against MAM insult.
ER  -

ŠTARK, Tibor; Jana RUDÁ; Fabio IANNOTI; Claudio D'ADDARIO; Roberta DI MARCO; Vladimír PEKAŘÍK; Eva DRAŽANOVÁ; Fabiana PISCITELLI; Monica BARI; Zuzana BABINSKÁ; Giovanni GIURDANELLA; Martina DI BARTOLOMEO; Salvatore SALOMONE; Alexandra ŠULCOVÁ; Mauro MACCARRONE; Carsten WOTJAK; Zenon STARČUK; Filippo DRAGO; Raphael MECHOULAM; Vincenzo DI MARZO a Vincenzo MICALE. Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. \textit{Neuropharmacology}. Oxford: Pergamon-Elsevier Science LTD, 2019, roč.~146, č.~1, s.~212-221. ISSN~0028-3908. Dostupné z: https://doi.org/10.1016/j.neuropharm.2018.11.035.

Přehled o publikaci